{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-050525","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.907698+00:00","generated_at":"2026-06-03T04:11:19.912648+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lyra Therapeutics Q1 net loss $22.5M; ENLIGHTEN 1 Phase 3 results expected in May 2024","bullets":["Cash $87.1M at March 31, 2024 vs $102.8M at Dec 31, 2023; cash runway into Q1 2025.","Net loss $22.5M vs $16.3M in Q1 2023; R&D expense $18.2M (up $5.6M YoY).","ENLIGHTEN 1 pivotal Phase 3 data for LYR-210 in CRS expected in May 2024.","ENLIGHTEN 2 enrollment completion expected H2 2024; LYR-220 end-of-Phase 2 meeting with FDA anticipated H2 2024.","BEACON Phase 2 data for LYR-220 to be presented at COSM on May 15, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-050525","json":"https://secwatch.observer/filing/0000950170-24-050525.json","markdown":"https://secwatch.observer/filing/0000950170-24-050525.md","text":"https://secwatch.observer/filing/0000950170-24-050525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024050525/0000950170-24-050525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024050525/lyra-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:11:19.912648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c5d2c9878f001a18410aec729b27090114fc32c","claim":"Lyra Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023..","evidence_excerpt":"Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024050525/0000950170-24-050525-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}